M&T Bank Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? M&T Bank Corporation trades at $251.93 (market cap $36.27B), while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: M&T Bank Corporation pays a 2.39% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MTB | XBI | |
|---|---|---|
Market Cap | $36.27B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $254.04 | $164.28 |
52-Week Low | $178.63 | $86.92 |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Trailing returns across standard periods
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →